Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKB105
- Development stage
- Phase 2
- Lead developer
- Kelun-Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**SKB105** (also known as CR-003) is a next-generation antibody-drug conjugate (ADC) developed by Sichuan Kelun-Biotech for solid tumors. It comprises a fully human IgG1 monoclonal antibody targeting **integrin beta-6 (ITGB6)**, overexpressed in many solid tumors with minimal normal tissue expression, conjugated via a stable, clinically validated cleavable linker to a **topoisomerase 1 inhibitor payload** using proprietary Kthiol irreversible conjugation technology to enhance stability, tumor-specific delivery, and reduce off-target toxicity. Preclinical data show favorable efficacy, safety, and pharmacokinetics; a Phase 1/2 monotherapy trial in solid tumors is planned for Q1 2026 in Greater China by Kelun-Biotech, with Crescent Biopharma holding ex-Greater China rights and combination studies with CR-001 (PD-1 x VEGF bispecific) anticipated.[1][7]
- Other names
- CR-003CR003CR 003
02
Targets
ITGB6 (Integrin beta-4)
Beyond the preview
Go deeper on SKB105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKB105.